Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated CIK cells armed with anti-CD3-MUC1 bispecific antibody in advanced gastric cancer
NCT03554395Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Apr 2018
- Primary completion
- May 2020
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of activated cytokine-induced killer cells + anti-CD3-MUC1 bispecific antibody in gastric cancer (GC), sponsored by Fuda Cancer Hospital. Planned start Apr 2018; status: withdrawn.
02
Drugs
activated cytokine-induced killer cells + anti-CD3-MUC1 bispecific antibody
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03554395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554395.